As long as a combination of PD-L1- and CXCR4-targeted therapies have been tested for TNBC patients [64], a relevant treatment combination could be tested in prostate cancer patients to examine their therapeutic impact. The gene discussed is CXCR4; the disease is prostate carcinoma.